These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6134845)

  • 41. Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration.
    Lachman L; Howden CW
    Am J Gastroenterol; 2000 Jan; 95(1):57-61. PubMed ID: 10638559
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Endoscopic double-blind controlled trial of ranitidine vs placebo in the short-term treatment of duodenal ulcer.
    Dobrilla G; de Pretis G; Felder M; Chilovi F
    Hepatogastroenterology; 1981 Feb; 28(1):49-52. PubMed ID: 6111528
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chronic toxicity of ebrotidine in rats and dogs.
    Romero A; Grau MT; Villamayor F; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):498-504. PubMed ID: 9205752
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevention of gastric ulcer relapse induced by indomethacin in rats by a mutein of basic fibroblast growth factor.
    Satoh H; Asano S; Maeda R; Murakami I; Inada I; Sato F; Shino A
    Jpn J Pharmacol; 1997 Mar; 73(3):229-41. PubMed ID: 9127818
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pre-operative ranitidine. Effect of a single intravenous dose on pH and volume of gastric aspirate.
    Maile CJ; Francis RN
    Anaesthesia; 1983 Apr; 38(4):324-6. PubMed ID: 6133481
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of BMY-25368, a potent and long-acting histamine H2-receptor antagonist, on gastric secretion and aspirin-induced gastric lesions in the dog.
    Cavanagh RL; Buyniski JP
    Aliment Pharmacol Ther; 1989 Jun; 3(3):299-313. PubMed ID: 2577694
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Twice daily nizatidine or ranitidine is superior to once daily dosing in elevating 24 h intragastric pH in patients with duodenal ulcer disease.
    Thomson AB; Mahachai V; Bailey RJ; Kirdeikis P; Zuk L; Marriage B; Simpson I; Jamali F
    J Gastroenterol Hepatol; 1996 Dec; 11(12):1171-6. PubMed ID: 9034938
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of ranitidine on quality of gastric ulcer healing compared with famotidine: a randomized, controlled, multicenter trial.
    Higuchi K; Watanabe T; Tominaga K; Shiba M; Nakagawa K; Uno H; Kitada K; Satoh H; Chono S; Uchida T; Fujiwara Y; Arakawa T
    Int J Clin Pharmacol Res; 2005; 25(4):187-94. PubMed ID: 16402635
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Furan H2-antagonist ranitidine inhibits pentagastrin-stimulated gastric secretion stronger than cimetidine.
    Domschke W; Lux G; Domschke S
    Gastroenterology; 1980 Dec; 79(6):1267-71. PubMed ID: 6108279
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of gastric acid secretion in the dog by the H2-receptor antagonists, ranitidine, cimetidine, and metiamide.
    Daly MJ; Humphray JM; Stables R
    Gut; 1980 May; 21(5):408-12. PubMed ID: 6107261
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Effect of ranitidine on secretion of gastric intrinsic factor and absorption of vitamin B 12].
    Bélaïche J; Zittoun J; Marquet J; Nurit Y; Yvart J
    Gastroenterol Clin Biol; 1983 Apr; 7(4):381-4. PubMed ID: 6135642
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Effects of ranitidine, a new histamine H2-receptor antagonist, on secretagogue-stimulated gastric secretion in Heidenhain pouch dogs (author's transl)].
    Ohtsuki H; Okabe S
    Nihon Yakurigaku Zasshi; 1981 Dec; 78(6):539-47. PubMed ID: 6120885
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of ranitidine and cimetidine on pentagastrin and insulin stimulated gastric secretion.
    Sheers R; Roberts N
    Scand J Gastroenterol Suppl; 1981 Jun; 69():51-9. PubMed ID: 6119783
    [No Abstract]   [Full Text] [Related]  

  • 54. New histamine H2-receptor antagonists.
    Domschke S; Domschke W
    Hepatogastroenterology; 1980 Jun; 27(3):163-8. PubMed ID: 6109690
    [No Abstract]   [Full Text] [Related]  

  • 55. [Ranitidine in the treatment of duodenal ulcer. Initial clinical experience with 33 patients].
    Noya G; Dettori G; Antona C; Niolu P; Muscas A; Marongiu G; Biglioli P
    Minerva Med; 1983 Mar; 74(13):691-3. PubMed ID: 6132353
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dynamics of gastric acid inhibition by ranitidine in duodenal ulcer patients.
    Konturek SJ; Obtułowicz W; Kwiecień N; Kopp B; Oleksy J
    Digestion; 1981; 22(3):119-25. PubMed ID: 6116636
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of ranitidine on gastric mucus, pepsin and hydrochloric acid secretion in patients with duodenal ulcer.
    Gabryelewicz A; Sarosiek J; Laszewicz W
    Acta Med Pol; 1981; 22(4):335-9. PubMed ID: 6128866
    [No Abstract]   [Full Text] [Related]  

  • 58. New drugs. H2 receptor antagonists--cimetidine and ranitidine.
    Feely J; Wormsley KG
    Br Med J (Clin Res Ed); 1983 Feb; 286(6366):695-7. PubMed ID: 6130817
    [No Abstract]   [Full Text] [Related]  

  • 59. [Evaluation of various cardiovascular parameters during the intravenous administration of ranitidine].
    Azzolini A; Gianrossi R; Livi S; Nizzo MC; Oliveri M; Mangini P
    Boll Soc Ital Biol Sper; 1982 Jul; 58(14):891-4. PubMed ID: 6127091
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The outcome of reflux oesophagitis: does drug-induced remission mean cure?
    Savarino V; Celle G
    Ital J Gastroenterol Hepatol; 1998 Oct; 30(5):475-7. PubMed ID: 9836098
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.